logo
Plus   Neg
Share
Email

5 Top Gainers In Healthcare Sector (CODX, SXTC, TMDI...)

pharmaup-jan30-lt.jpg

The following are some of today's top gainers in the pharma/biotech sector.

1. Co-Diagnostics Inc. (CODX)

Gained 101.80% to close Wednesday's (Jan.30) trading at $2.24.

Co-Diagnostics is a molecular diagnostics company.

News: The Company announced the sale of $3 million of preferred shares, convertible to common stock at a fixed price of $1.20 per share. The transaction has paved way for effectively eliminating the Company's debt and additional capital infusion.

2. China SXT Pharmaceuticals Inc. (SXTC)

China SXT Pharmaceuticals is a pharmaceutical company developing traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use.

Gained 43.81% to close Wednesday's trading at $6.04.

News: No news

Recent event:

On January 4, 2019, the Company's shares made their debut on the NASDAQ at an offering price of $4.00 per share.

3. Eyenovia Inc. (EYEN)

Gained 25.10% to close Wednesday's trading at $3.29.

News: The Company's phase III study evaluating MicroStat for pharmacologic mydriasis (eye dilation), dubbed MIST-1, met the primary endpoint.

The second phase III study in the MicroStat program for pharmacologic mydriasis, dubbed MIST-2 study, is underway, with results expected to be announced in short order.

4. Titan Medical Inc. (TMDI)

Titan Medical is a medical device company focused on the design and development of a robotic surgical system for application in minimally invasive surgery.

Gained 23.87% to close Wednesday's trading at $3.84.

Near-term Catalysts:

-- Complete the required human confirmatory studies for its SPORT Surgical System under an Investigational Device Exemption during the second half of 2019.

The SPORT Surgical System is a single-port robotic surgical system, being developed for one or more of gynecologic, urologic, colorectal or general abdominal procedures.

-- File for the CE mark for SPORT Surgical System by year-end 2019.

5. Alder Biopharmaceuticals, Inc. (ALDR)

Gained 17.47% to close Wednesday's trading at $14.12.

News: No news

Near-term Catalyst:

The Company's lead investigational product is Eptinezumab, a monoclonal antibody for migraine prevention. The Biologics License Application for Eptinezumab is expected to be submitted this quarter. (Q1, 2019).

For comments and feedback contact: editorial@rttnews.com

Follow RTT